Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 3

1.

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.

Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA; ACCOMPLISH Trial investigators.

Lancet. 2010 Apr 3;375(9721):1173-81. doi: 10.1016/S0140-6736(09)62100-0. Epub 2010 Feb 18.

PMID:
20170948
[PubMed - indexed for MEDLINE]
2.

Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.

Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchi Y, Uchida S, Kuwahara M, Yamazaki T; Japanese Lasartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators.

Clin Exp Nephrol. 2003 Sep;7(3):221-30.

PMID:
14586719
[PubMed - indexed for MEDLINE]
3.

[Acute kidney failure and losartan: a recently observed event of antagonists of angiotensin II AT1 receptors].

Dionisio P, Valenti M, Caramello E, Bergia R, Cravero R, Berto IM, Agostini B, Monaci G, Bajardi P.

Minerva Urol Nefrol. 2000 Sep;52(3):123-5. Italian.

PMID:
11227361
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk